HONG KONG – Ever since the Hong Kong Stock Exchange (HKEX) lowered the listing bar for biotech startups that are yet to generate revenue, the bourse keeps receiving applications from biotech firms both inside and outside China.
HONG KONG – Hangzhou, China-based Adlai Nortye Biopharma Co. Ltd. said Tuesday it partnered with Novartis AG to obtain the worldwide rights to BKM-120 (buparlisib), a selective PI3K inhibitor, to treat head and neck cancer, adding one more lead product to the Chinese company's oncology pipeline.
HONG KONG – South Korean company Alteogen Inc. is working with its U.S. partner, Lynkogen Inc., of New Jersey, to develop novel GLP-1 mimetic and alpha-1 antitrypsin (A1AT) fusion proteins for the treatment of nonalcoholic steatohepatitis (NASH) and metabolic diseases. Clinical trials could begin in two years' time.
HONG KONG – Ever since the Hong Kong Stock Exchange (HKEX) lowered the listing bar for biotech startups that are yet to generate revenue, the bourse keeps receiving applications from biotech firms both inside and outside China.
HONG KONG – China's Luye Pharma Group Ltd. has emerged as a global biotech player by leveraging partnerships around the world, and its 24-year journey is a case study of how a Chinese company can expand, both acquire and protect intellectual property (IP) and deal with cultural challenges that come with global operations.
HONG KONG – China's Luye Pharma Group Ltd. has emerged as a global biotech player by leveraging partnerships around the world, and its 24-year journey is a case study of how a Chinese company can expand, both acquire and protect intellectual property (IP) and deal with cultural challenges that come with global operations.
